Telomir Pharmaceuticals, Inc. has filed a registration statement with the SEC to sell over 5 million shares of its common stock. This move is aimed at increasing liquidity and providing existing shareholders with an opportunity to sell their holdings. The registration statement was filed on October 27, 2026, and is a significant step for the company as it seeks to navigate the competitive landscape of the pharmaceutical industry.

Telomir Pharmaceuticals operates in the pharmaceutical preparations sector, as classified under SIC 2834. The company is listed on the Nasdaq under the ticker symbol TELO. This registration statement follows a series of recent filings, including an 8-K on October 6, 2026, which detailed previous securities transactions.

According to the filing, the company is registering a total of 5,292,810 shares. This includes 4,900,750 outstanding shares held by certain selling securityholders and 392,060 shares that may be issued upon the exercise of placement agent common stock purchase warrants. The shares are being offered as part of a private placement that occurred earlier this month.

In the recent private placements, Telomir Pharmaceuticals sold approximately 4.84 million shares at a price of $1.16 per share on October 5, 2026, and an additional 57,447 shares at $1.13 per share on October 9, 2026. These transactions were part of agreements with selling securityholders, which also included warrants for future shares. The company will not receive proceeds from the sale of the shares by the selling securityholders, but it may receive funds upon the exercise of the warrants.

This registration is crucial for Telomir as it allows the selling securityholders to offer and sell their shares in a regulated manner. The company has agreed to bear all expenses related to the registration, while the selling securityholders will cover any discounts or commissions associated with the sale.

The filing does not specify what happens next, but it indicates that the selling securityholders may offer these shares through various methods, including public or private transactions. This flexibility could enhance the liquidity of the shares and attract more investors.

As Telomir Pharmaceuticals continues to expand its presence in the pharmaceutical preparations industry, this registration statement underscores its commitment to providing opportunities for its shareholders while navigating the competitive market landscape.